Navigation Links
Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
Date:12/6/2010

g-term disease-free survival in all patients(3,4). When a patient relapses or becomes refractory, treatment options include high-dose chemotherapy, usually followed by stem cell transplantation(3,4). The use of transplantation has resulted in improved outcomes in patients with relapsed disease, but still 40% to 50% of these patients subsequently relapse(2). There is currently no standard of care for patients who relapse or are refractory following these treatments(3,4).

Study detailsThis Phase II clinical trial evaluated the efficacy and safety of oral LBH589 in patients with refractory/relapsed classical Hodgkin lymphoma who had received prior treatment with high-dose chemotherapy and autologous stem cell transplant(9).

The primary outcome measure was objective response rate to therapy. Secondary outcome measures included response rate based on central review of CT scan/MRI, time to response, duration of response, progression-free survival rate and safety and tolerability of treatment(9).

As of the data analysis, 129 patients had been enrolled and treated. Patients had received a median number of four (range 2-7) prior systemic regimens, including combination regimens involving drugs such as gemcitabine, vinca-alkaloids or platinum-based chemotherapies. At a median follow-up of 9.6 months, a reduction in measurable tumor size was observed in 96 (74%) patients; responses were observed in 35 patients (5 complete responses, 30 partial responses; overall response rate 27%). Median progression-free survival was 6.1 months (10.5 months among responders)(1).

Common adverse events (mostly grade 1 or 2) included diarrhea, nausea, fatigue, vomiting, anorexia, dysguesia, asthenia, constipation, leukopenia and muscle spasms. Common related grade 3/4 adverse events included thrombocytopenia, anemia and neutropenia. Thrombocytopenia was reversible with dose hold or modification and was manageable long term, with only 5% treatment discontinuation
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... ANGELES , Dec. 17, 2014  ImmunoCellular ... the US Patent and Trademark Office (USPTO) has ... ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting six ... The claims of US Patent No. 8,871,211, which ... neural cancer by administering a dendritic cell composition ...
(Date:12/17/2014)... Dec. 17, 2014 PCCA received the ... ( http://bit.ly/1382OkS ) program seal for best practices ... program highlights medical practices, materials and goods that ... Children affected by autism often have ... exacerbated by ingredients found in food and medicine ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... of the "Inferior Vena Cava (IVC) Filters - ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... is projected to reach US$435 million by 2016. The ... 39% (2015) of the global value while ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4
(Date:12/17/2014)... Mass. (PRWEB) December 17, 2014 ... of Osteopathic Medicine (ACOM), which welcomed its inaugural ... Desktop Infrastructure (VDI) to seamlessly support bring your ... – and teaching – experience. The solution, comprised ... NetScaler , Dell server and storage infrastructure ...
(Date:12/17/2014)... Francisco, CA (PRWEB) December 17, 2014 A ... Stanford Center for Longevity, today, in reaction to a recent ... emerging science of brain training and derogated the efficacy of ... that they agreed with the parts of the center’s statement ... they believed the center had also overstated its case, in ...
(Date:12/17/2014)... 2014 Now in its second year, ... of the best in senior living and home care ... to communities and agencies that have received outstanding online ... the nearly 100,000 providers currently listed on SeniorAdvisor.com, only ... SeniorAdvisor.com Best of 2015 Awards are located all over ...
(Date:12/17/2014)... By Alan Mozes ... -- In the world of infectious diseases, one worrisome phenomenon ... into people. The process -- known as zoonosis -- ... they look for signs that an animal-borne disease might make ... on just such a development -- and the culprits in ...
(Date:12/17/2014)... 2014 (HealthDay News) -- Greater participation in music classes ... Researchers followed kids in the nonprofit Harmony Project, ... in Los Angeles. Over two years, children who ... how the brain processes speech and reading, compared to ... benefits of active participation in music classes occurred in ...
Breaking Medicine News(10 mins):Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 3Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Music Classes Boost Language Skills, Study Says 2
... research on new presbyopia treatments now available in ... in today,s Scientific Program of the 2010 Joint Meeting ... Middle East-Africa Council of Ophthalmology (MEACO). The AAO-MEACO meeting ... and is in session October 16 through 19 at ...
... , TUESDAY, Oct. 19 (HealthDay News) -- Although designed ... Web site doesn,t help patients select the best facility ... contends. Hospitals submit data quarterly from the Surgical ... and infection, in order to receive annual Medicare payment ...
... of Defense has awarded researchers at the University ... Development Award to develop the next generation of ... on a tube" is designed to provide continuous ... injury or other neurological emergencies and is capable ...
... women may be able to safely avoid getting bone density tests ... of problems, a new study suggests. "If a woman,s ... need to be re-screened in two years or three years, because ... Margaret L. Gourlay of the University of North Carolina at Chapel ...
... Pediatric health care work force planning efforts are ... physician assistants, especially in plans to alleviate the ... from four new studies of pediatric nurse practitioners, ... physician assistants published online today in the journal ...
... Serena Gordon HealthDay Reporter , MONDAY, Oct. 18 ... sugar levels before non-heart surgery had a higher risk of ... diabetes, researchers have found. And, patients who hadn,t been ... surgery had a higher risk of death in the year ...
Cached Medicine News:Health News:New vision correction options for baby boomers 2Health News:New vision correction options for baby boomers 3Health News:New vision correction options for baby boomers 4Health News:Web Site for Hospital Comparisons Is Faulty: Study 2Health News:University of Cincinnati neurotrauma team awarded $2.1M to test 'lab on a tube' 2Health News:University of Cincinnati neurotrauma team awarded $2.1M to test 'lab on a tube' 3Health News:Fewer Bone Screens May Be OK for Some Older Women 2Health News:Few nurse practitioners, physician assistants pursue careers in pediatric health 2Health News:Even Well-Controlled Diabetes May Present Post-Surgery Risk 2Health News:Even Well-Controlled Diabetes May Present Post-Surgery Risk 3
The Cellabs Rapimal (P.f.) is a rapid and sensitive in vitro immunochromatography assay system for the detection of HRP-2 antigen produced by P. falciparum at the merozoite (red blood cell) stage o...
192 Test HRP-II Enzyme Immunoassay for the presence of Plasmodium falciparum infection....
Malaria device / strip (2 line, PAN specific-pLDH)...
... Uni-Gold™ Pf Malaria Test is a ... presence of Plasmodium falciparum ... an antigen-capture assay detecting presence of ... protein II (PfHRP- II), which is ...
Medicine Products: